RANK Ligand
Research News and Information

Sunday, November 22, 2009

Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling.

29 Nov 2009 The role of OxLDL in the generation and progression of atherosclerosis is well admitted. In addition, it is well known that atherosclerosis is often accompanied by perturbations in bone remodeling, resulting in osteoporosis. In the current studies, ... Read more...

Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.

29 Nov 2009 Receptor activator NF-kappaB ligand (RANKL)-activated signaling is essential for osteoclast differentiation, activation and survival. Caffeic acid phenethyl ester (CAPE), a natural NF-kappaB inhibitor from honeybee propolis has been shown to have ... Read more...

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

29 Nov 2009 The receptor activator of nuclear factor-kappaB ligand (RANKL) plays a critical role in the differentiation and bone resorptive activity of osteoclasts. Recently, the development of anti-resorptive agents from natural substances has become a subject ... Read more...

Latest indexed articles for 'RANK Ligand'

These are the very latest articles for this heading:

• Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. 29 Nov 2009
• Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. 29 Nov 2009
• Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. 29 Nov 2009
• CCR5 down-regulates osteoclast function in orthodontic tooth movement. 30 Oct 2009
• Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts. 7 Oct 2009
• Accelerated cartilage resorption by chondroclasts during bone fracture healing in osteoprotegerin-deficient mice. 7 Oct 2009
• Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. 6 Oct 2009
• Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. 29 Sep 2009
• Late-stage osteoporosis drugs illustrate challenges in the field. 29 Sep 2009
• Sustained and localized in vitro release of BMP-2/7, RANKL, and tetracycline from FlexBone, an elastomeric osteoconductive bone substitute. 29 Sep 2009
• Influence of lipopolysaccharide and interleukin-6 on RANKL and OPG expression and release in human periodontal ligament cells. 29 Sep 2009
• Local delivery of EGF-liposome mediated bone modeling in orthodontic tooth movement by increasing RANKL expression. 27 Sep 2009
• Direct effects of osteoprotegerin on human bone cell metabolism. 9 Sep 2009
• Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. 6 Sep 2009
• Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome: a novel molecular mechanism. 30 Aug 2009
• Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. 30 Aug 2009
• Osteoblast and osteoclast differentiation in an in vitro three-dimensional model of bone. 30 Aug 2009
• Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. 30 Aug 2009
• Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. 30 Aug 2009
• Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. 28 Aug 2009

See a longer list of these articles.

Technical information about 'RANK Ligand'

Definition: A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.

Registry Number: 0

Descriptor UI: D053245

Alternative terms: RANK Ligand; Osteoclast Differentiation Factor; Differentiation Factor, Osteoclast; Osteoprotegerin Ligand; RANKL Protein; Receptor Activator of Nuclear Factor-kappa B Ligand; Receptor Activator of Nuclear Factor kappa B Ligand; TNF Superfamily, Member 11; TRANCE Protein; Tumor Necrosis Factor Ligand Superfamily Member 11; Tumor Necrosis Factor-Related Activation-Induced Cytokine; Tumor Necrosis Factor Related Activation Induced Cytokine; OPGL Protein; Receptor Activator of Nuclear Factor-kappaB Ligand; Receptor Activator of Nuclear Factor kappaB Ligand;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.644.276.374.750.562; D12.644.276.972.562; D12.776.467.374.750.562; D12.776.467.972.562; D23.529.374.750.562; D23.529.972.562;

History Note: 2007(1997)